why choose us

First received: April 14, 2023

Clinical Trial: A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Adults

Study Status: Completed

Recruit Status: RECRUITING

Condition: Epstein-Barr Virus Infection

Study Type: INTERVENTIONAL


Official Title: A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, 2-Part, Dose-Ranging Study of an EBV Candidate Vaccine, mRNA-1195, in Healthy Adults 18 to 55 Years of Age

Brief Summary: The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy adults (18 to 55 years of age).

Read more